Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of postmenopausal women with hormone receptor positive breast cancer (see "clinical trials"). the safety and efficacy of neoadjuvant use has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; microcrystalline cellulose; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; macrogol 400 - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - early breast cancer: adjuvant treatment of early breast cancer in post-menopausal women with estrogen/progesterone receptor positive disease. advanced breast cancer: first line treatment of advanced breast cancer in post-menopausal women with estrogen/progesterone receptor positive disease. treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. patients with estrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: macrogol 300; titanium dioxide; hypromellose; povidone; sodium starch glycollate; magnesium stearate; lactose monohydrate - early breast cancer: adjuvant treatment of early breast cancer in post-menopausal women with oestrogen/progesterone receptor positive disease. advanced breast cancer: first line treatment of advanced breast cancer in post-menopausal women with oestrogen/progesterone receptor positive disease. treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. patients with oestrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to arimidex,

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; poloxamer; calcium hydrogen phosphate dihydrate; citric acid monohydrate; sodium starch glycollate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - raloxifene gh is proposed to be used for:,1. the prevention and treatment of osteoprosis in post-menopausal women,2. the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis,3. the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer,high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer >1.66% (based on the modified gail model). among the factors included in the modified gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.

Australia - English - Department of Health (Therapeutic Goods Administration)

actor pharmaceuticals pty ltd - tibolone, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; ascorbyl palmitate; magnesium stearate; potato starch - indications ? short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.,? second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.,after careful selection of users, tibogen should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). tibogen should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - estradiol, quantity: 1 mg (equivalent: estradiol hemihydrate, qty 1.03 mg); dydrogesterone, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; hypromellose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; iron oxide red; macrogol 400 - hormone replacement therapy (hrt) in oestrogen deficiency associated with natural or artificial menopause in women with an intact uteri. prevention of postmenopausal bone mineral density loss in women. for initiation and continuation of treatment of postmenopausal symptoms, the lowest possible effective dose for the shortest duration should be used with the goal being short term use.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; lactose monohydrate; sodium starch glycollate; hypromellose; macrogol 8000; colloidal anhydrous silica; maize starch; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc - for the treatment of postmenopausal women with hormone receptor positive breast cancer (see clinical trials). the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; potato starch; ascorbyl palmitate; magnesium stearate; mannitol - - short-term treatment of symptoms resulting from the natural or surgical menopause in postmenopausal women.,- second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - risedronate sodium hemipentahydrate, quantity: 5.74 mg (equivalent: risedronate sodium, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; microcrystalline cellulose; crospovidone; hyprolose; titanium dioxide; hypromellose; macrogol 8000; colloidal anhydrous silica; iron oxide yellow; macrogol 400 - ? treatment of osteoporosis,? treatment of glucocorticoid-induced osteoporosis,? preservation of bone mineral density in patients on long term corticosteroid therapy